For anyone who has spent a frantic morning in a pediatrician's waiting room with a feverish child, the promise is clear: a definitive answer in twenty minutes, from your own kitchen counter. Sensopore, a Cambridge-based healthtech spinout from MIT, is building the hardware to make that possible. The company is developing a compact, at-home diagnostic device that uses electrochemical biosensors to detect common infectious diseases, pairing the physical unit with a mobile app for telehealth connectivity and potential prescriptions [MIT News, Sep 2025].
The Academic Wedge
The company's foundation is its scientific co-founder, Prof. Ariel Furst, whose research into new methods for disease detection earned her a spot on the 2025 Talented 12 list from Chemical & Engineering News [Chemical & Engineering News, 2025]. The technology centers on a potentiostat integrated with a mobile application that communicates via Bluetooth and WiFi [Perplexity Sonar Pro, 2025]. The team is rounded out by CEO Yaasha Hasan and co-founder Maximiliano Jara Fornerod [1, 2026] [Laidlaw Scholars Network].
The Early-Stage Footprint
Sensopore's current footprint is that of a classic academic incubator project. It has participated in the MIT Delta-v accelerator and was featured in The Engine's Blueprint Showcase [The Engine, 2026] [MIT Sloan, 2025]. Its disclosed funding is limited to $20,000 in non-dilutive grants [Sensopore website, 2025].
| Founder | Role | Notable Background / Recognition |
|---|---|---|
| Prof. Ariel Furst | Co-Founder | Named to Chemical & Engineering News 2025 Talented 12 list. |
| Yaasha Hasan | CEO & Co-Founder | Laidlaw Scholar. |
| Maximiliano Jara Fornerod | Co-Founder | Selected for cancer tech accelerator program. |
The Regulatory Hurdle
The ambition to diagnose infectious diseases at home places Sensopore squarely in the crosshairs of the U.S. Food and Drug Administration. Any device claiming to detect a specific pathogen for the purpose of guiding treatment would require FDA clearance, a process that demands rigorous clinical validation. For a pre-seed company with minimal funding, this represents a significant, capital-intensive barrier.
The Patient Population in Focus
The target is patients with suspected common bacterial or viral infections, such as strep throat, influenza, or possibly UTIs. Sensopore's vision is to collapse that multi-hour, multi-location ordeal into a single, twenty-minute at-home procedure with a direct link to a clinician.
Sources
- [MIT News, Sep 2025] Demo Day features hormone-tracking sensors, desalination systems, and other innovations | https://news.mit.edu/2025/demo-day-features-hormone-tracking-sensors-desalination-systems-and-other-innovations-0910
- [Chemical & Engineering News, 2025] Prof. Ariel Furst named to Talented 12 list | https://cen.acs.org/people/awards/Talented-12-2025/102/web/2025/08
- [Sensopore website, 2025] Company website | https://www.sensopore.com/
- [1, 2026] Maximiliano Jara Fornerod LinkedIn profile | https://www.linkedin.com/in/maximiliano-jara-fornerod/
- [Laidlaw Scholars Network] Yaasha Hasan profile | https://laidlawscholars.network/users/yaasha-hasan
- [The Engine, 2026] The Blueprint Showcase | https://engine.xyz/blueprint-showcase-2
- [MIT Sloan, 2025] 22 MIT startups to watch in 2025 | https://mitsloan.mit.edu/ideas-made-to-matter/22-mit-startups-to-watch-2025